Use and risk management of carvedilol for the treatment of heart failure in the community in England: Results from a modified prescription-event monitoring study

Drug Safety

Volumn 32, Issue 1, 2009, Pages 43-54

  Aurich Barrera, Beate ^a,b   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ADULT; AGED; ARTICLE; BRADYCARDIA; COHORT ANALYSIS; CONFUSION; DIZZINESS; DRUG DOSE TITRATION; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; HEART FAILURE; HUMAN; HYPOTENSION; LASSITUDE; MAJOR CLINICAL STUDY; MALAISE; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK MANAGEMENT; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CARBAZOLES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENGLAND; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; PROPANOLAMINES; QUESTIONNAIRES; RISK MANAGEMENT;

EID: 58149345744     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932010-00004     Document Type: Article

References (29)

1. Foody JM, Farrell MH, Krumholz HM. Beta-Blocker therapy in heart failure: scientific review. JAMA 2002 Feb 20; 287 (7): 883-9
2. Bouvy ML, Heerdink ER, Leufkens HG, et al. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail 2003 Mar; 5 (2): 195-200
3. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002 Nov 23; 360 (9346): 1631-9
4. Cox JL, Ramer SA, Lee DS, et al. Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Can J Cardiol 2005 Mar 15; 21 (4): 337-43
5. Simko RJ, Stanek EJ. Treatment patterns for heart failure in a primary care environment. Am J Manag Care 1997 Nov; 3 (11): 1669-76
6. Mehta DK. British National Formulary. 50th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005
7. National Institute for Clinical Excellence (NICE). Chronic heart failure; management of chronic heart failure in adults in primary and secondary care, clinical guideline 5. 2006 [online]. Available from URL: http://www.nice.org.uk/ guidance [Accessed 2006 Apr 15]
8. Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester, UK: John Wiley & Sons Ltd, 2007: 307-16
9. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for the diagnosis of diseases of the heart and great vessels. 9th ed. Boston (MA): Little Brown & Co., 1994: 253-6
10. Roche Products Ltd. Eucardic: summary of product characteristic. Welwyn Garden City: Roche Products Ltd, 2000
11. CIOMS/WHO. International guidelines for biomedical research involving human subjects. Geneva: CIOMS, WHO, 2002
12. Department of Health. Supplementary operational guidelines for NHS Research Ethics Committees - November 2000. Multi-centre research in the NHS - the process of ethical review demonstrated when there is no local researcher [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_4006696 [Accessed 2007 Nov 3]
13. Royal College of Physicians. Guidelines on the practice of ethical committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996
14. Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001 Dec 1; 358 (9296): 1872-3
15. Martin RM, Biswas PN, Freemantle SN, et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998 Nov; 46 (5): 505-11
16. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004 Feb; 147 (2): 324-30
17. Tandon P, McAlister FA, Tsuyuki RT, et al. The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med 2004 Apr 12; 164 (7): 769-74
18. Hood S, Taylor S, Roeves A, et al. Are there age and sex differences in the investigation and treatment of heart failure? A population-based study. Br J Gen Pract 2000; 50 (456): 559-63
19. Majeed A, Williams J, de LS, et al. Management of heart failure in primary care after implementation of the National Service Framework for Coronary Heart Disease: a cross-sectional study. Public Health 2005 Feb; 119 (2): 105-11
20. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004 Apr 21; 43 (8): 1423-9
21. Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (Carvedilol ACE-Inhibitor Remodeling Mild CHF EvaluatioN). Eur J Heart Fail 2004 Jun; 6 (4): 467-75
22. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005 Feb 15; 45 (4): 525-30
23. Rickli H, Steiner S, Muller K, et al. Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial). Eur J Heart Fail 2004 Oct; 6 (6): 761-8
24. Fink B, Schwemmer M, Fink N, et al. Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. J Cardiovasc Pharmacol 1999 Dec; 34 (6): 800-5
25. Watanabe H, Kakihana M, Ohtsuka S, et al. double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 1998 Nov; 32 (5): 1194-200
26. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996 Dec 1; 94 (11): 2793-9
27. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003 Feb 12; 289 (6): 712-8
28. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349-55
29. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006 Feb; 151 (2): 444-50